X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (70) 70
Publication (13) 13
Book / eBook (8) 8
Patent (6) 6
Conference Proceeding (4) 4
Book Review (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32) 32
humans (29) 29
female (24) 24
male (23) 23
hematology (19) 19
middle aged (18) 18
life sciences (17) 17
oncology (17) 17
aged (16) 16
aged, 80 and over (14) 14
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
cancer (12) 12
treatment outcome (12) 12
adult (11) 11
chemotherapy (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
rituximab (9) 9
elderly-patients (8) 8
cyclophosphamide (7) 7
follow-up studies (7) 7
lymphomas (7) 7
non-hodgkins-lymphoma (7) 7
prognosis (7) 7
therapy (7) 7
hematology, oncology and palliative medicine (6) 6
human necessities (6) 6
hygiene (6) 6
lymphoma, large b-cell, diffuse - drug therapy (6) 6
medical or veterinary science (6) 6
preparations for medical, dental, or toilet purposes (6) 6
specific use of cosmetics or similar toiletpreparations (6) 6
survival (6) 6
survival analysis (6) 6
adolescent (5) 5
analysis (5) 5
animals (5) 5
bortezomib (5) 5
disease progression (5) 5
economic policy (5) 5
medical research (5) 5
medicine, experimental (5) 5
multiple myeloma - drug therapy (5) 5
antibodies, monoclonal, murine-derived - therapeutic use (4) 4
clinical trials (4) 4
cohort studies (4) 4
disease-free survival (4) 4
kaplan-meier estimate (4) 4
lymphoma (4) 4
lymphoma, large b-cell, diffuse - mortality (4) 4
lymphoma, large b-cell, diffuse - pathology (4) 4
macroeconomics (4) 4
multiple myeloma (4) 4
plus rituximab (4) 4
proportional hazards models (4) 4
prospective studies (4) 4
recurrence (4) 4
response criteria (4) 4
time factors (4) 4
young adult (4) 4
aged patients (3) 3
aggressive lymphoma (3) 3
anthracyclines (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
architecture (3) 3
b-cell lymphoma (3) 3
bendamustine (3) 3
chemotherapy plus rituximab (3) 3
chop chemotherapy (3) 3
cyclophosphamide - administration & dosage (3) 3
cyclophosphamide - adverse effects (3) 3
cyclophosphamide - therapeutic use (3) 3
dlbcl (3) 3
doxorubicin - administration & dosage (3) 3
doxorubicin - adverse effects (3) 3
doxorubicin - therapeutic use (3) 3
drug administration schedule (3) 3
drug resistance, neoplasm (3) 3
europe (3) 3
france (3) 3
human health and pathology (3) 3
immunochemotherapy (3) 3
lenalidomide (3) 3
lymphoma, follicular - mortality (3) 3
lymphoma, follicular - pathology (3) 3
multiple myeloma - mortality (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasm staging (3) 3
ofatumumab (3) 3
prednisone - administration & dosage (3) 3
prednisone - adverse effects (3) 3
prednisone - therapeutic use (3) 3
risk factors (3) 3
tumors (3) 3
unemployment (3) 3
vincristine (3) 3
vincristine - administration & dosage (3) 3
abridged index medicus (2) 2
abstracts (2) 2
acvbp (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 460 - 468
Summary Background Diffuse large B-cell lymphoma is a common cancer in elderly patients. Although treatment has been standardised in younger patients, no... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE RITUXIMAB | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | RESPONSE CRITERIA | ONCOLOGY | AGGRESSIVE LYMPHOMAS | MALIGNANT-LYMPHOMAS | NON-HODGKINS-LYMPHOMA | COMPREHENSIVE GERIATRIC ASSESSMENT | DETUDE-DES-LYMPHOMES | CHOP CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Prospective Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Aged, 80 and over | Vincristine - administration & dosage | Female | France | Odds Ratio | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Risk Factors | Rituximab | Treatment Outcome | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Analysis of Variance | Belgium | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - adverse effects | Doxorubicin - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Anthracyclines | Cyclophosphamide | Chemotherapy | Corticosteroids | Oncology, Experimental | Aged patients | Product development | Prednisone | Lymphomas | Research | Cancer | Toxicity | Albumin | Clinical trials | Multivariate analysis | Doxorubicin | Survival | Vincristine | Side effects | Motivation | Age | rituximab | B-cell lymphoma | Geriatrics | Neutropenia | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1128 - 1135
Journal Article
Haematologica, ISSN 0390-6078, 08/2011, Volume 96, Issue 8, pp. 1136 - 1143
Background As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed... 
Follicular lymphoma | Rituximab | Autologous stem cell transplantation | FDG-PET | follicular lymphoma | RESPONSE CRITERIA | autologous stem cell transplantation | PLUS RITUXIMAB | RANDOMIZED CONTROLLED-TRIAL | POSITRON-EMISSION-TOMOGRAPHY | POOR-PROGNOSIS | NON-HODGKIN-LYMPHOMA | AGGRESSIVE LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | HEMATOLOGY | ELDERLY-PATIENTS | rituximab | Doxorubicin - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Cyclophosphamide - adverse effects | Case-Control Studies | Cyclophosphamide - therapeutic use | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Bleomycin - therapeutic use | Vindesine - adverse effects | Vindesine - therapeutic use | Adult | Female | Prednisone - adverse effects | Lymphoma, Large B-Cell, Diffuse - pathology | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Bleomycin - adverse effects | Lymphoma, Large B-Cell, Diffuse - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Index Medicus | Original
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 25, pp. 2941 - 2948
Journal Article
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 14, pp. 4224 - 4230
Purpose: Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone)... 
THERAPY | BORTEZOMIB | EFFICACY | ONCOLOGY | SAFETY | ELDERLY-PATIENTS
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2013, Volume 109, Issue 10, pp. 844 - 851
Journal Article
Haematologica, ISSN 0390-6078, 2015, Volume 100, Issue 2, pp. e56 - e59
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1066 - 1073
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 13, pp. 2869 - 2876
Journal Article